Moreover, large multicenter trials of anti–TNF-α therapy in heart failure patients have not only failed to demonstrate clinical benefit, but suggest targeting TNF-α blockade may adversely affect the course of the disease (50). The gene discussed is TNF; the disease is heart failure.